This article was originally published in The Rose Sheet
Fourth quarter and fiscal year 2004 sales and earnings are expected to meet or exceed Wall Street estimates, firm says Sept. 22. Results are bolstered by Alberto's strategy of "advertising at record levels behind solid Alberto VO5, St. Ives and TRESemme product propositions, and by focusing on fewer and bigger brands, geographies and customers," according to CEO Howard Bernick. Alberto VO5, St. Ives, and TRESemme are all "more profitable today than ever before, and are better positioned than ever to continue to thrive in 2005 and future years here in the U.S. and overseas," exec adds...
You may also be interested in...
Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-seven guidance documents have been posted on the tracker since its last update.
Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.